Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
561
LV function and geometry: Exercise cohort.
Published 2024“…Additionally, miR-22 and miR-30e decreased with exercise and mapped to a localized inflammatory process, the inflammasome (NLRP-3, whereby a 2-fold decrease in NLRP-3 mRNA occurred with exercise (p < 0.05).…”
-
562
S1 Graphical abstract -
Published 2024“…Additionally, miR-22 and miR-30e decreased with exercise and mapped to a localized inflammatory process, the inflammasome (NLRP-3, whereby a 2-fold decrease in NLRP-3 mRNA occurred with exercise (p < 0.05).…”
-
563
-
564
-
565
-
566
-
567
-
568
-
569
-
570
DataSheet2_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.pdf
Published 2022“…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
-
571
DataSheet1_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.PDF
Published 2022“…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
-
572
-
573
-
574
-
575
-
576
-
577
-
578
-
579
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
580
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: